Recherche dans les collections de brevets nationales et internationales
Une partie du contenu de cette demande n'est pas disponible pour le moment.
Si cette situation persiste, contactez-nous auObservations et contact
1. (WO2015177501) VECTEURS LENTIVIRAUX
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

CLAIMS

A lentiviral vector pseudotyped with hemagglutinin-neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, wherein said lentiviral vector comprises a promoter and a transgene, and wherein the lentiviral vector lacks an(y) intron positioned between said promoter and said transgene.

The lentiviral vector according to Claim 1 , wherein the lentiviral vector is selected from the group consisting of a Human immunodeficiency virus (HIV) vector, a Simian immunodeficiency virus (SIV) vector, a Feline immunodeficiency virus (FIV) vector, an Equine infectious anaemia virus (EIAV) vector, and a Visna/maedi virus vector.

The lentiviral vector according to Claims 1 or 2, wherein lentiviral vector is a SIV vector.

The lentiviral vector according to any preceding claim, wherein the respiratory paramyxovirus is a Sendai virus.

The lentiviral vector according to any of the preceding claims, wherein the promoter is selected from the group consisting of a cytomegalovirus (CMV) promoter, elongation factor 1 a (EF1 a) promoter, and a hybrid human CMV enhancer/EF1 a (hCEF) promoter.

6. The lentiviral vector according to any of the preceding claims, wherein the vector comprises a hybrid human CMV enhancer/EF1 a (hCEF) promoter.

7. The lentiviral vector according to any of the preceding claims, wherein the transgene is selected from CFTR, DNAH5, DNAH11, DNAI1, and DNAI2, Alpha-1 Antitrypsin {A 1AT), Surfactant Protein B (SFTPB), Factor VI II, von Willebrand Factor or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF).

The lentiviral vector according to any of the preceding claims, wherein the transgene encodes CFTR.

The lentiviral vector according to any one of claims 1 to 7, wherein the transgene encodes A1AT.

The lentiviral vector according to any one of claims 1 to 7, wherein the transgene encodes FVIII.

The lentiviral vector according to any one of Claims 1 to 7, wherein the promoter is a hCEF promoter and the transgene encodes CFTR.

The lentiviral vector according to any one of Claims 1 to 7 or 9, wherein the promoter is a hCEF promoter and the transgene encodes A1AT.

The lentiviral vector according to any one of Claims 1 to 7 or 9, wherein the promoter is a hCEF or CMV promoter and the transgene encodes FVIII.

A method of producing lentivirus, said method comprising the following steps:

(a) growing cells in suspension;

(b) transfecting the cells with one or more plasmids;

(c) adding a nuclease;

(d) harvesting the lentivirus;

(e) adding trypsin; and

(f) purification.

The method according to Claim 14, wherein steps (a)-(f) are carried out sequentially.

The method according to Claim 14 or Claim 15, wherein the cells are HEK293T or 293T/17 cells.

17. The method according to Claims 14 to 16, wherein the addition of the nuclease is at the pre-harvest stage.

18. The method according to Claims 14 to 17, wherein the addition of trypsin is at the post-harvest stage.

19. The method according to Claims 14 to 18, wherein the purification step comprises a chromatography step.

20. A method of treating a disease, the method comprising administering a lentiviral vector of any one of Claims 1 to 13 to a subject.

21. The method according to Claim 20, wherein the disease is a lung disease selected from: cystic fibrosis (CF); Primary Ciliary Dyskinesia (PCD); Surfactant Protein B (SP-B) deficiency; Alpha 1 -antitrypsin Deficiency (A1AD); Pulmonary Alveolar Proteinosis (PAP); and Chronic obstructive pulmonary disease (COPD).

22. The method according to Claim 20, wherein the transgene is Factor VIII and the disease is Haemophilia.

23. A lentiviral vector according to any one of Claims 1 to 7, 8 or 1 1 for use in treatment of CF.

24. A lentiviral vector according to any one of Claims 1 to 7, 9 or 12 for use in treatment of A1AT deficiency.

25. A lentiviral vector according to any one of Claims 1 to 7, 10 or 13 for use in treatment of Haemophilia.

26. A host cell comprising the vector according to any one of Claims 1 -13.

27. A composition comprising a vector according to any one of Claims 1-13, and a pharmaceutically-acceptable carrier.